Thermal behavior of sodium alendronate

Albu, Paul; Doca, Sorin Cristian; Anghel, Andrei; Vlase, Gabriela

doi:10.1007/s10973-016-5745-7

Cited by 17 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second step, between 230 and 298 °C, can be attributed to the mass loss of ammonia released in the degradation of the drug, since the observed value, based on Figure 3, was 5% and the theoretical value is 5.20%. These results are in accordance with the literature 54 …”

Section: Resultssupporting

confidence: 94%

“…This result is in agreement with the theoretical value of mass loss 54 . The mass loss observed in Figure 3 was around 16%, a value close to the theoretical (16.61%).…”

Section: Resultssupporting

confidence: 91%

“…Lastly, the third step, above 300°C, shown a continuous mass loss and the DTG curves present four peaks, indicating different steps of thermal degradation (Figure 4). According to Albu et al ., 54 a complete pyrolysis would lead to the formation of NaH 3 P 2 O 7 , which would promote a theoretical mass loss close to 31.7%. However, what was observed experimentally, according to Figure 3, was a loss of mass around 24%.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Polycaprolactone/alendronate systems intended for production of biomaterials

Silva

Pereira

Patricio

et al. 2021

J of Applied Polymer Sci

View full text Add to dashboard Cite

Sodium alendronate (ALD) is a bisphosphonate used to treat osteoporosis. However, its oral administration has been associated with side effects as gastroesophageal reflux. Moreover, there are some particularities for the intake of the medicine, which also hinder the patient's compliance, for example, the instruction that it has to be taken with an empty stomach, 30 to 60 min before breakfast and avoid the decubitus position after using the drug. Therefore, biomaterials for applications in osteoporotic bones are a good alternative. Thus, this work aimed to produce a Polycaprolactone (PCL) and ALD‐based powder as a supply to build biomaterials by selective laser sintering, compression molding (CM), solvent casting (SC), among others. The powder was produced by coating the ALD particles with PCL and films were produced by SC and CM techniques. The samples were characterized by Scanning Electron Microscopy, Energy‐dispersive X‐ray spectroscopy, X‐ray diffraction, Fourier transform infrared spectrometry and thermal analysis. Furthermore, the drug release was evaluated by UV–Vis spectroscopy. Results showed that ALD particles were successfully coated by PCL and applied to the production of biomaterials, highlighting its potential in the treatment of osteoporosis.

show abstract

Section: Resultssupporting

confidence: 94%

“…This result is in agreement with the theoretical value of mass loss 54 . The mass loss observed in Figure 3 was around 16%, a value close to the theoretical (16.61%).…”

Section: Resultssupporting

confidence: 91%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Polycaprolactone/alendronate systems intended for production of biomaterials

Silva

Pereira

Patricio

et al. 2021

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…According to the diagrams in Figure 3, the mass loss between 116 and 149 o C (with a maximum at 130 0 C) is 3.56%. With pure ALE the mass loss for the same process is 16.2% [42]. It means that the quantity of ALE in the composite is 21.9% (considering the HA as very thermostable).…”

Section: Composite Characterizationmentioning

confidence: 98%

“…The question is if the thermal stability of ALE is changed. In a previous paper [42] the thermal behaviour of sodium alendronate was presented. It was proved that a deamination occurs at 260 o C, and a very sharp and good defined dehydration peak is present at 130 o C. This last one will be used for quantitative determinations.…”

Section: Composite Characterizationmentioning

confidence: 99%

The Use of Bisphosphonate-Hydroxyapatite Composite in Bone Augmentation

Doca¹,

Vlase²,

Vlase³

et al. 2020

Rev. Chim.

Self Cite

View full text Add to dashboard Cite

A good bone augmentation and regeneration depends essentially on the use of a high biomimetic hydroxyapatite, respectively of an osteoclast apoptosis promoting compound. The last one, used in oral or injectable form, leads to different gastrointestinal side effects. We suggested and studied, at non-clinical level, a composite of sodium alendronate linked on a biogene hydroxyapatite. The composite was obtained by putting an aqueous solution of alendronate into a suspension of hydroxyapatite in acetone. By physico-chemical methods the binding of alendronate (ALE) on hydroxyapatite was proved, the content of ALE in the composite being 22%. The patients can benefit from this composite due to a total elimination of gastrointestinal side effects as a consequence of limiting the bioactivity only locally.

show abstract